1
|
Liu W, Zhang Y, Li Q, Wang X, Wu Y, Shen H, Wang P. Advances of long non-coding RNAs in osteoclast differentiation and osteoporosis. Pathol Res Pract 2024; 260:155413. [PMID: 38981344 DOI: 10.1016/j.prp.2024.155413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 06/05/2024] [Accepted: 06/13/2024] [Indexed: 07/11/2024]
Abstract
INTRODUCTION Osteoclasts, which are responsible for bone resorption, are specialized multinucleated cells generated from monocyte/macrophage progenitor cells or hematopoietic stem cells (HSCs). Physiological bone remodeling can become pathological, such as osteoporosis, when osteoclastogenesis is out of balance. Thousands of long noncoding RNAs (lncRNAs) influence important molecular and biological processes. Recent research has revealed gene expression regulation function that numerous lncRNAs regulate nuclear domain organization, genome stability. Furthermore, the research of lncRNAs has substantial clinical implications for the treatment of existing and new diseases. AREAS COVERED In this review, we gather the most recent research on lncRNAs and their potential for basic research and clinical applications in osteoclast and osteoporosis. We also discuss the findings here in order to fully understand the role of lncRNAs in osteoclast differentiation and osteoporosis, as well as to provide a solid basis for future research exploring associated mechanisms and treatments. EXPERT OPINION LncRNA has been considered as an important role in the regulation of osteoclast differentiation and osteoporosis. It is exciting to investigate pathophysiological processes in osteoporosis and the therapeutic potential of lncRNAs. We hope that this review will offer promising prospects for the development of precision and individualized approaches to treatment.
Collapse
Affiliation(s)
- Wenjie Liu
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China; Guangdong Provincial Clinical Research Center for Orthopedic Diseases, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China
| | - Yunhui Zhang
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China
| | - Quanfeng Li
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China; Guangdong Provincial Clinical Research Center for Orthopedic Diseases, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China
| | - Xinglang Wang
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China; Guangdong Provincial Clinical Research Center for Orthopedic Diseases, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China
| | - Yanfeng Wu
- Center for Biotherapy, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China; Guangdong Provincial Clinical Research Center for Orthopedic Diseases, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China.
| | - Huiyong Shen
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China; Guangdong Provincial Clinical Research Center for Orthopedic Diseases, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China.
| | - Peng Wang
- Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China; Guangdong Provincial Clinical Research Center for Orthopedic Diseases, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen 518033, China.
| |
Collapse
|
2
|
Saginova D, Tashmetov E, Kamyshanskiy Y, Koshanova A, Arutyunyan M, Rustambek I. The histological assessment of new bone formation with zolendronic acid loaded bone allograft in rabbit femoral bone defect. J Med Life 2023; 16:616-622. [PMID: 37305828 PMCID: PMC10251371 DOI: 10.25122/jml-2022-0314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2022] [Accepted: 03/24/2023] [Indexed: 06/13/2023] Open
Abstract
The aim of this experimental study was to evaluate the effect of zolendronic acid (ZOL) combined with bone allograft prepared using the Marburg Bone Bank System on bone formation in the implant remodeling zone. Femoral bone defects with a diameter of 5 mm and a depth of 10 mm were created in 32 rabbits. Animals were divided into 2 similar groups: Group 1 (control), where defects were filled with bone allograft, and Group 2, where allograft was combined with ZOL. Eight animals from each group were sacrificed at 14- and 60-days post-surgery and bone defect healing was assessed using histopathological and histomorphometric analyses after 14 and 60 days. The results showed that new bone formation within the bone allograft was significantly greater in the control group than in the ZOL-treated group after 14 and 60 days (p<0.05). In conclusion, local co-administration of ZOL on heat-treated allograft inhibits allograft resorption and new bone formation in the bone defect.
Collapse
Affiliation(s)
- Dina Saginova
- Center for Applied Scientific Research, National Scientific Center of Traumatology and Orthopaedics named after academician N.D.Batpenov, Nur-Sultan, Kazakhstan
| | - Elyarbek Tashmetov
- Department of Surgical Diseases, Karaganda Medical University, Karaganda, Kazakhstan
| | - Yevgeniy Kamyshanskiy
- Institute of Pathology of the University Clinic, Karaganda Medical University, Karaganda, Kazakhstan
| | - Amina Koshanova
- Department of Surgical Diseases, Karaganda Medical University, Karaganda, Kazakhstan
| | - Marietta Arutyunyan
- Department of Surgical Diseases, Karaganda Medical University, Karaganda, Kazakhstan
| | - Ibrahim Rustambek
- Department of Surgical Diseases, Karaganda Medical University, Karaganda, Kazakhstan
| |
Collapse
|
3
|
Ogata K, Moriyama M, Matsumura-Kawashima M, Kawado T, Yano A, Nakamura S. The Therapeutic Potential of Secreted Factors from Dental Pulp Stem Cells for Various Diseases. Biomedicines 2022; 10:biomedicines10051049. [PMID: 35625786 PMCID: PMC9138802 DOI: 10.3390/biomedicines10051049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2022] [Revised: 04/18/2022] [Accepted: 04/27/2022] [Indexed: 11/16/2022] Open
Abstract
An alternative source of mesenchymal stem cells has recently been discovered: dental pulp stem cells (DPSCs), including deciduous teeth, which can thus comprise potential tools for regenerative medicine. DPSCs derive from the neural crest and are normally implicated in dentin homeostasis. The clinical application of mesenchymal stem cells (MSCs) involving DPSCs contains various limitations, such as high cost, low safety, and cell handling issues, as well as invasive sample collection procedures. Although MSCs implantation offers favorable outcomes on specific diseases, implanted MSCs cannot survive for a long period. It is thus considered that their mediated mechanism of action involves paracrine effects. It has been recently reported that secreted molecules in DPSCs-conditioned media (DPSC-CM) contain various trophic factors and cytokines and that DPSC-CM are effective in models of various diseases. In the current study, we focus on the characteristics of DPSC-CM and their therapeutic potential against various disorders.
Collapse
|
4
|
Extracorporeal Shock-Wave Therapy or Low-Level Laser Therapy: Which is More Effective in Bone Healing in Bisphosphonate Treatment? J Craniofac Surg 2020; 31:2043-2048. [DOI: 10.1097/scs.0000000000006506] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Piao H, Kim MH, Cui M, Choi G, Choy JH. Alendronate-Anionic Clay Nanohybrid for Enhanced Osteogenic Proliferation and Differentiation. J Korean Med Sci 2019; 34:e37. [PMID: 30718990 PMCID: PMC6356027 DOI: 10.3346/jkms.2019.34.e37] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2018] [Accepted: 12/13/2018] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Alendronate (AL), a drug for inhibiting osteoclast-mediated bone-resorption, was intercalated into an inorganic drug delivery nanovehicle, layered double hydroxide (LDH), to form a new nanohybrid, AL-LDH, with 1:1 heterostructure along the crystallographic C-axis. Based on the intercalation reaction strategy, the present AL-LDH drug delivery system (DDS) was realized with an enhanced drug efficacy of AL, which was confirmed by the improved proliferation and osteogenic differentiation of osteoblast-like cells (MG63). METHODS The AL-LDH nanohybrid was synthesized by conventional ion-exchange reaction and characterized by powder X-ray diffraction (PXRD), high-resolution transmission electron microscopy (HR-TEM), and Fourier transform infrared (FT-IR) spectroscopy. Additionally, in vitro efficacy tests, such as cell proliferation and alkaline phosphatase (ALP) activity, were analyzed. RESULTS The AL was successfully intercalated into LDH via ion-exchange reaction, and thus prepared AL-LDH DDS was X-ray single phasic and chemically well defined. The accumulated AL content in MG63 cells treated with the AL-LDH DDS nanoparticles was determined to be 10.6-fold higher than that within those treated with the intact AL after incubation for 1 hour, suggesting that intercellular permeation of AL was facilitated thanks to the hybridization with drug delivery vehicle, LDH. Furthermore, both in vitro proliferation level and ALP activity of MG63 treated with the present hybrid drug, AL-LDH, were found to be much more enhanced than those treated with the intact AL. This is surely due to the fact that LDH could deliver AL drug very efficiently, although LDH itself does not show any effect on proliferation and osteogenic differentiation of MG63 cells. CONCLUSION The present AL-LDH could be considered as a promising DDS for improving efficacy of AL.
Collapse
Affiliation(s)
- Huiyan Piao
- Department of Chemistry and Nanoscience, Center for Intelligent Nano-Bio Materials, Ewha Womans University, Seoul, Korea
| | - Myung Hun Kim
- Department of Chemistry and Nanoscience, Center for Intelligent Nano-Bio Materials, Ewha Womans University, Seoul, Korea
| | - Meiling Cui
- Department of Chemistry and Nanoscience, Center for Intelligent Nano-Bio Materials, Ewha Womans University, Seoul, Korea
| | - Goeun Choi
- Department of Chemistry and Nanoscience, Center for Intelligent Nano-Bio Materials, Ewha Womans University, Seoul, Korea
- Institute of Tissue Regeneration Engineering, Dankook University, Cheonan, Korea
| | - Jin-Ho Choy
- Department of Chemistry and Nanoscience, Center for Intelligent Nano-Bio Materials, Ewha Womans University, Seoul, Korea
| |
Collapse
|
6
|
Di Nisio C, Zizzari VL, Zara S, Falconi M, Teti G, Tetè G, Nori A, Zavaglia V, Cataldi A. RANK/RANKL/OPG signaling pathways in necrotic jaw bone from bisphosphonate-treated subjects. Eur J Histochem 2015; 59:2455. [PMID: 25820558 PMCID: PMC4378212 DOI: 10.4081/ejh.2015.2455] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2014] [Revised: 12/17/2014] [Accepted: 12/18/2014] [Indexed: 12/23/2022] Open
Abstract
Osteonecrosis of the jaw (ONJ) is a chronic complication affecting long-term bisphosphonate-treated subjects, recognized by non-healing exposed bone in the maxillofacial region. The pathophysiological mechanism underlying ONJ has not been fully elucidated. The aim of the present study was to investigate the role of RANK/RANKL/OPG signaling pathway and, in parallel, to evaluate angiogenic and matrix mineralization processes in jaw bone necrotic samples obtained from bisphosphonate-treated subjects with established ONJ. Necrotic bone samples and native bone samples were processed for Light and Field Emission in Lens Scanning Electron Microscope (FEISEM) analyses, for Real-Time RT-PCR to evaluate the gene expression of TNFRSF11A (RANK), TNFSF11 (RANKL), and TNFSF11B (OPG) and for immunohistochemical analyses of VEGF and BSP expression. Morphological analyses performed by Light microscope and FEISEM show empty osteocytic lacunae and alteration of lamellar organization with degradation of the mineralized bone matrix in necrotic bone samples. A significant increase in TNFRSF11A, TNFSF11, TRAF6 and NFAT2 gene expression, and a reduction of TNFSF11B gene transcription level compared is also showed in necrotic bone compared to control samples. No significant difference of VEGF expression is evidenced, while lower BSP expression in necrotic bone compared to healthy samples is found. Even if the pathogenesis of bisphosphonate-associated ONJ remains unknown, a link between oral pathogens and its development seems to exist. We suppose lipopolysaccharide produced by bacteria colonizing and infecting necrotic bone and the surrounding viable area could trigger RANK/RANKL/OPG signaling pathway and, in this context, osteoclasts activation could be considered as a protective strategy carried out by the host bone tissue to delimitate the necrotic area and to counteract infection.
Collapse
|
7
|
Rini GB, Sprini D, Migliaccio S, Basili S, Strollo R, Dieli F, Napoli N. Vγ9 Vδ2 T lymphocytes activation as a novel approach to test efficacy of different bisphosphonates. Endocrine 2015; 48:346-8. [PMID: 25096911 DOI: 10.1007/s12020-014-0303-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2013] [Accepted: 05/14/2014] [Indexed: 12/27/2022]
Affiliation(s)
- Giovam Battista Rini
- Dipartimento di Medicina Interna e Specialistica (DIMIS), Università di Palermo, Palermo, Italy,
| | | | | | | | | | | | | |
Collapse
|
8
|
Bisphophonates in CKD patients with low bone mineral density. ScientificWorldJournal 2013; 2013:837573. [PMID: 24501586 PMCID: PMC3899701 DOI: 10.1155/2013/837573] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2013] [Accepted: 11/27/2013] [Indexed: 02/08/2023] Open
Abstract
Patients with chronic kidney disease-mineral and bone disorder (CKD-MBD) have a high risk of bone fracture because of low bone mineral density and poor bone quality. Osteoporosis also features low bone mass, disarranged microarchitecture, and skeletal fragility, and differentiating between osteoporosis and CKD-MBD in low bone mineral density is a challenge and usually achieved by bone biopsy. Bisphosphonates can be safe and beneficial for patients with a glomerular filtration rate of 30 mL/min or higher, but prescribing bisphosphonates in advanced CKD requires caution because of the increased possibility of low bone turnover disorders such as osteomalacia, mixed uremic osteodystrophy, and adynamic bone, even aggravating hyperparathyroidism. Therefore, bone biopsy in advanced CKD is an important consideration before prescribing bisphosphonates. Treatment also may induce hypocalcemia in CKD patients with secondary hyperparathyroidism, but vitamin D supplementation may ameliorate this effect. Bisphosphonate treatment can improve both bone mineral density and vascular calcification, but the latter becomes more unlikely in patients with stage 3-4 CKD with vascular calcification but no decreased bone mineral density. Using bisphosphonates requires considerable caution in advanced CKD, and the lack of adequate clinical investigation necessitates more studies regarding its effects on these patients.
Collapse
|
9
|
Gagliato D, Chavez-MacGregor M. Adjuvant bisphosphonates in breast cancer: has the time come? BREAST CANCER MANAGEMENT 2013. [DOI: 10.2217/bmt.13.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
SUMMARY Bone metabolism is highly affected by changes in ovarian function, which is a common consequence of the treatment of breast cancer patients. Osteopenia and osteoporosis increase the risk of fractures, which are associated with profound loss in quality of life. Bisphosphonates are used with the objective of preventing bone loss in patients with osteoporosis, but data suggest that agents such as zoledronic acid might play a role in the prevention of metastatic disease and therefore have been evaluated in numerous randomized trials in the adjuvant setting. This review article will discuss and analyze the available data regarding the use of bisphosphonates in the adjuvant setting for breast cancer patients. It will focus on the use of bisphosphonates as anticancer agents, but will also discuss the use of these agents for the prevention of bone loss.
Collapse
Affiliation(s)
- Debora Gagliato
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1155 Herman P Pressler CPB5.3550, Houston, TX 77030-4009, USA
| | - Mariana Chavez-MacGregor
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1155 Herman P Pressler CPB5.3550, Houston, TX 77030-4009, USA.
| |
Collapse
|
10
|
Shi Y, Su Z, Li S, Chen Y, Chen X, Xiao Y, Sun M, Ping Q, Zong L. Multistep targeted nano drug delivery system aiming at leukemic stem cells and minimal residual disease. Mol Pharm 2013; 10:2479-89. [PMID: 23646913 DOI: 10.1021/mp4001266] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Refractory leukemia remains the most common therapeutic problem in clinical treatment of leukemia. The key therapy of refractory leukemia is to kill, thoroughly, the minimal residual disease and leukemia stem cells in the highly vascularized red marrow areas. In this study, two new conjugates, alendronate-polyethylene glycol (100) monostearate and folate-polyethylene glycol (100) monostearate, were synthesized to develop a multistep targeting nanostructured lipid carriers by enhancing drug transport to the high bone turnover areas adjacent to the red marrow and targeting the minimal residual disease and leukemia stem cells. This dual targeting system demonstrated a great binding affinity to hydroxyapatite, a model component of bone minerals, and higher cell uptake (in the form of carriers but not drug) and cytotoxicity in the K562 cell line, a leukemia cell line with overexpressed folate receptors, were observed in vitro compared to unmodified carriers, especially when the cells were pretreated and the receptors were up-regulated by all-trans retinoic acid. The comodel test of K562 cells and HA showed that this dual targeting system could desorb from bone surface and be taken up by leukemia cells. For the in vivo study, this dual targeting system exhibited a significant increase in plasma half-life and could specifically accumulate in the bone tissue of rats or mice after intravenous injection. Ex vivo imaging of mice femurs and confocal laser scanning microscope imaging of mice femur slices further confirmed that this dual targeting system could favorably deposit to the osteoblast-enriched areas of high bone turnover in regions of trabecular bone surrounded by red marrow. In vivo antitumor activity in K562/BALB/c-nu leukemia mice showed that the treatment of this dual targeting system significantly reduced the white blood cell (WBC) number in peripheral blood and bone marrow to the normal level. In conclusion, this dual targeting system could precisely target to the regions where the minimal residual disease and leukemia stem cells are located and then be specifically uptaken in large amounts, which is a valuable target for refractory leukemia therapy.
Collapse
Affiliation(s)
- Yongping Shi
- Department of Pharmaceutics, Key Lab of State Natural Medicine, China Pharmaceutical University, Nanjing 210009, PR China
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Belfrage O, Isaksson H, Tägil M. Local treatment of a bone graft by soaking in zoledronic acid inhibits bone resorption and bone formation. A bone chamber study in rats. BMC Musculoskelet Disord 2012; 13:240. [PMID: 23217097 PMCID: PMC3528664 DOI: 10.1186/1471-2474-13-240] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2011] [Accepted: 11/26/2012] [Indexed: 01/08/2023] Open
Abstract
Background Bone grafts are frequently used in orthopaedic surgery. Graft remodelling is advantageous but can occur too quickly, and premature bone resorption might lead to decreased mechanical integrity of the graft. Bisphosphonates delay osteoclastic bone resorption but may also impair formation of new bone. We hypothesize that these effects are dose dependent. In the present study we evaluate different ways of applying bisphosphonates locally to the graft in a bone chamber model, and compare that with systemic treatment. Methods Cancellous bone grafts were placed in titanium chambers and implanted in the tibia of 50 male rats, randomly divided into five groups. The first group served as negative control and the grafts were rinsed in saline before implantation. In the second and third groups, the grafts were soaked in a zoledronic acid solution (0.5 mg/ml) for 5 seconds and 10 minutes respectively before being rinsed in saline. In the fourth group, 8 μL of zoledronic acid solution (0.5 mg/ml) was pipetted onto the freeze-dried grafts without rinsing. The fifth group served as positive control and the rats were given zoledronic acid (0.1 mg/kg) systemically as a single injection two weeks after surgery. The grafts were harvested at 6 weeks and analysed with histomorphometry, evaluating the ingrowth distance of new bone into the graft as an equivalent to the anabolic osteoblast effect and the amount (bone volume/total volume; BV/TV) of remaining bone in the remodelled graft as equivalent to the catabolic osteoclast effect. Results In all chambers, almost the entire graft had been revascularized but only partly remodelled at harvest. The ingrowth distance of new bone into the graft was lower in grafts soaked in zoledronic acid for 10 minutes compared to control (p = 0.007). In all groups receiving zoledronic acid, the BV/TV was higher compared to control. Conclusions This study found a strong inhibitory effect on bone resorption by bisphosphonates but also a limited inhibition of the ingrowth of new bone. Local treatment at surgery resulted in stronger inhibition of both resorption and bone formation compared to systemic treatment.
Collapse
Affiliation(s)
- Ola Belfrage
- Department of Orthopedics, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden.
| | | | | |
Collapse
|
12
|
Graziani F, Vescovi P, Campisi G, Favia G, Gabriele M, Gaeta GM, Gennai S, Goia F, Miccoli M, Peluso F, Scoletta M, Solazzo L, Colella G. Resective Surgical Approach Shows a High Performance in the Management of Advanced Cases of Bisphosphonate-Related Osteonecrosis of the Jaws: A Retrospective Survey of 347 Cases. J Oral Maxillofac Surg 2012; 70:2501-7. [PMID: 22883322 DOI: 10.1016/j.joms.2012.05.019] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2011] [Revised: 05/15/2012] [Accepted: 05/16/2012] [Indexed: 01/09/2023]
|
13
|
Basi DL, Hughes PJ, Thumbigere-Math V, Sabino M, Mariash A, Lunos SA, Jensen E, Gopalakrishnan R. Matrix Metalloproteinase-9 Expression in Alveolar Extraction Sockets of Zoledronic Acid–Treated Rats. J Oral Maxillofac Surg 2011; 69:2698-707. [DOI: 10.1016/j.joms.2011.02.065] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2010] [Revised: 12/23/2010] [Accepted: 02/12/2011] [Indexed: 11/17/2022]
|
14
|
|
15
|
Mortier PP, Van Waes FE, Masschelein KG, Heugebaert TS, Stevens CV. Synthesis of N-vinyl 2,2-bisphosphonoaziridines from 1,1-bisphosphono-2-aza-1,3-dienes. Tetrahedron Lett 2011. [DOI: 10.1016/j.tetlet.2011.05.149] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
|
16
|
Chiplunkar S, Dhar S, Wesch D, Kabelitz D. gammadelta T cells in cancer immunotherapy: current status and future prospects. Immunotherapy 2011; 1:663-78. [PMID: 20635991 DOI: 10.2217/imt.09.27] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
gammadelta T lymphocytes are a distinct T-cell subset that display unique features with respect to T-cell receptor (TCR) gene usage, tissue tropism and antigen recognition. Phosphoantigens contributed by a dysregulated mevalonate pathway or the bacterial nonmevalonate pathway and aminobisphosphonates are capable of activating Vgamma9Vdelta2 T cells. With the aid of synthetic phosphoantigens, large-scale expansion of gammadelta T cells and their adoptive transfer into human hosts is now possible. The present review summarizes triumphs and tribulations of clinical trials using gammadelta T-cell immunotherapy. Adoptive transfer of phosphoantigen-activated gammadelta T cells or coadministration with aminobisphosphonates/cytokines/monoclonal antibodies appear to be promising approaches for cancer immunotherapy. It can be predicted that a comprehensive understanding of the molecular interactions of this unique T-cell subset with other key immune regulators (dendritic cells and regulatory T cells) will provide an impetus to bring this modality of treatment from bench to bedside.
Collapse
Affiliation(s)
- Shubhada Chiplunkar
- Advanced Centre for Treatment, Research & Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India.
| | | | | | | |
Collapse
|
17
|
|
18
|
Liu X, Bao C, Hu J, Yin G, Luo E. Effects of clodronate combined with hydroxyapatite on multi-directional differentiation of mesenchymal stromal cells. Arch Med Sci 2010; 6:670-7. [PMID: 22419923 PMCID: PMC3298333 DOI: 10.5114/aoms.2010.17079] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2010] [Revised: 05/07/2010] [Accepted: 06/13/2010] [Indexed: 11/30/2022] Open
Abstract
INTRODUCTION Bisphosphonates (BPs) can be locally used to improve the osteogenesis around hydroxyapatite (HA) implants. However, there are almost no reports discussing the effects of BPs in the bonding state with HA on bone mesenchymal stromal cells (BMSCs). Clodronate is a BP widely used in clinical practice. This study was designed to evaluate the effects of clodronate combined with HA on BMSCs' multi-directional differentiation. MATERIAL AND METHODS The HA and clodronate-HA complex were prepared. BMSCs were isolated from Sprague-Dawley rat bone marrow and then the cells were cultured with both HA and clodronate-HA. The method of transcriptional and translational assay (MTT) and multi-directional induction (including osteogenic, adipogenic, and myogenic differentiation) were used to evaluate the effect of clodronate-HA on BMSC differentiation. RESULTS Scanning electron microscopy indicated active proliferation of the cells on clodronate-HA and HA. MTT of BMSCs cultured on clodronate-HA and HA demonstrated no significant differences between the two groups. BMSCs differentiated into osteocytes, adipocytes, and myocytes after being cultured with both clodronate-HA and HA. This indicated that BMSCs still retained multi-directional capability. The alkaline phosphatase activity of osteogenic induced BMSCs of both groups had no significant difference. However, there was a significant difference in total protein found between them. CONCLUSIONS The results suggest that clodronate in the bonding state with HA has no obvious inhibition of the proliferation and activity of BMSCs on the complex, and there was no evidence of a negative effect on multi-directional capability of the BMSCs.
Collapse
Affiliation(s)
- Xian Liu
- West China Stomatology College, State Key Laboratory of Oral Disease, Sichuan University, Sichuan Province, China
| | - Chongyun Bao
- West China Stomatology College, State Key Laboratory of Oral Disease, Sichuan University, Sichuan Province, China
| | - Jing Hu
- West China Stomatology College, State Key Laboratory of Oral Disease, Sichuan University, Sichuan Province, China
| | - Guozhu Yin
- West China Stomatology College, State Key Laboratory of Oral Disease, Sichuan University, Sichuan Province, China
| | - En Luo
- West China Stomatology College, State Key Laboratory of Oral Disease, Sichuan University, Sichuan Province, China
- Division of Oral Biology, Tufts University School of Dental Medicine, Boston, MA, USA
| |
Collapse
|
19
|
Scheper M, Chaisuparat R, Cullen K, Meiller T. A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis. FIBROGENESIS & TISSUE REPAIR 2010; 3:6. [PMID: 20359336 PMCID: PMC2859744 DOI: 10.1186/1755-1536-3-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/21/2009] [Accepted: 04/01/2010] [Indexed: 11/17/2022]
Abstract
Background Bisphosphonate (BP)-associated osteonecrosis of the jaw (ONJ) has been reported in patients receiving intravenous BP, particularly zoledronic acid (ZA). The purpose of this study was to develop an in vitro model representative of the effects BP has on soft tissue secondary to its release from bone. Human gingival fibroblasts and oral epithelial cell lines were exposed to various concentrations (0-10 μM) of ZA using dentine discs (DDs) as a direct carrier of BP, which were exposed for 24 hours to ZA in normal medium (NM), washed in phosphate-buffered saline (PBS) and placed in a new co-culture with the cells. The cells were allowed to proliferate until they grew over the bone discs and then the discs either were left unchelated, or were chelated using 0.001% EDTA or EGTA to release BP from the discs and to observe the cellular effects. Direct effects were determined using direct and fluorescent imaging. Apoptotic effects were determined by vital stain, terminal dUTP nick-end labeling, and annexin V studies. The effect on cell proliferation was determined by mitochondrial tetrazolium salt assay. The level of BP release was determined based on the effect of BP directly on cells, using the DDs or the supernatant fluids resulting from chelation. Results A dose-response effect was seen on imaging, and effects on apoptosis and cell proliferation were observed with increasing ZA concentrations liberated from the DDs, particularly after calcium cleavage and release of ZA from the DDs with a variety of chelating agents. Apoptotic effects were observed microscopically after chelation at 24 hours. Release of ZA was confirmed by extracting medium from non-chelated and chelated cell culture models with DDs and applying this medium to untreated fresh cell cultures, providing appropriate controls. Conclusions The results from this study demonstrate that low concentrations of ZA released from bone can rapidly and directly affect the oral mucosal tissues, initially through the induction of apoptosis and long term through the inhibition of cell proliferation. These findings provide an in vitro model for a soft-tissue mechanistic component in the initiation and/or progression of ONJ.
Collapse
Affiliation(s)
- Ma Scheper
- Department of Oncology and Diagnostic Sciences and the Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, 650 W Baltimore St, Baltimore, MD, 21201, USA.
| | | | | | | |
Collapse
|
20
|
Neville-Webbe HL, Coleman RE. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer 2010; 46:1211-22. [PMID: 20347292 DOI: 10.1016/j.ejca.2010.02.041] [Citation(s) in RCA: 74] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2010] [Accepted: 02/23/2010] [Indexed: 11/19/2022]
Abstract
Bisphosphonates (BPs) are potent inhibitors of osteoclast-mediated bone resorption, which is increased when cancer cells invade bone. BPs are an established treatment for cancer that has spread to bone, and effectively reduce pain and other skeletal-related events. New directions in metastatic bone disease (MBD) include personalised BP therapy, such as using bone markers to guide frequency of BP administration and bone targeting agents such as denosumab (AMG 162). Clinical trials strongly suggest that denosumab might play a defined role in the future management of MBD. In terms of potential anti-cancer activity, early data tentatively suggest that zoledronic acid might have a role to play in the prevention of metastatic disease, though whether this is a direct effect on cancer cells, or indirect via the bone marrow micro-environment, or both, is as yet undiscovered. The definitive answer as to the role of adjuvant BP in early cancer is being addressed, with over 20,000 patients with breast, prostate or lung cancer currently participating in adjuvant BP randomised trials. The results of these trials should be available in the next few years, and this will establish whether BPs given early in the course of cancer will be able to prevent the formation of metastases, bone or otherwise.
Collapse
Affiliation(s)
- H L Neville-Webbe
- Academic Department of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK.
| | | |
Collapse
|
21
|
The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 2009; 16:689-93. [PMID: 19240658 DOI: 10.1097/gme.0b013e318194cafd] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
OBJECTIVE Observational and experimental studies support that osteoporosis and atherosclerosis are two related phenomena. The aim of the present study was to investigate the probable effect of alendronate sodium, which is used in the treatment of osteoporosis, on carotid artery intima-media thickness (IMT), the lipid profile, and apolipoprotein A-I (ApoA-I) and apolipoprotein B (ApoB) levels, which are known to have a role in the atherosclerotic process. METHODS Carotid artery IMT was measured in 39 women in whom alendronate 70 mg/week was started due to osteoporosis and in 33 control participants at the start and the 6th and 12th months of the study. Triglyceride, high-density lipoprotein, low-density lipoprotein, ApoA-I, and ApoB levels were also measured at the same time points, and ApoB/ApoA-I rates were calculated. RESULTS Among the basal values, only the ApoA-I level was significantly lower in the alendronate group (P < 0.01). IMT measurement results (mean [SE]) of the alendronate group were 0.622 [0.015], 0.616 [0.014], and 0.597 [0.013] mm; those of the control group were 0.600 [0.010], 0.611 [0.011], and 0.620 [0.011] mm, respectively. In both groups, the difference between the start and 12-month values was significant (P < 0.05). A significant difference was not determined in the triglyceride and lipid measurement results between the groups and also within groups. ApoA and ApoB levels at the start and the 12th month of the study were as follows: 159.8 [3.6], 162.2 [3.4] (P > 0.05) and 96.2 [4.2], 101.5 [4.5] (P > 0.05) in the control group and 145.1 [4.0], 173.7 [4.3] (P < 0.05) and 98.7 [3.9], 84.6 [3.3] (P < 0.05) in the alendronate group, respectively. The ratios of ApoB/ApoA-I were 0.611 [0.029] is to 0.636 [0.031] (P > 0.05) in the control group and 0.703 [0.04] is to 0.498 [0.0] (P < 0.05) in the alendronate group. CONCLUSIONS We concluded that alendronate sodium resulted in a significant decrease in IMT during a 1-year period compared with matched controls. Also, alendronate was associated with a positive effect on the ApoB/ApoA-I ratio.
Collapse
|
22
|
Vovk AI, Kononets LA, Tanchuk VY, Drapailo AB, Kalchenko VI, Kukhar VP. Thiacalix[4]arene as molecular platform for design of alkaline phosphatase inhibitors. J INCL PHENOM MACRO 2009. [DOI: 10.1007/s10847-009-9607-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
23
|
Hoefert S, Schmitz I, Tannapfel A, Eufinger H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 2009; 14:271-84. [PMID: 19536569 DOI: 10.1007/s00784-009-0300-6] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2008] [Accepted: 06/02/2009] [Indexed: 01/25/2023]
Abstract
The aim of this study was to evaluate a possible role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw (ONJ) and to discuss an etiological model. Bone samples from 35 patients with ONJ were analyzed. Control samples were taken from five patients with osteomyelitis (OM), ten patients with osteoradionecrosis, seven patients with osteoporosis and bisphosphonate medication without signs of ONJ, and six osteoporotic elderly patients. Samples were examined using scanning electron microscopy. In 54% of the bone samples of patients with ONJ, microcracks were seen. Inflammatory and connective tissue reactions within the microcracks were evident in 82% of the cases, indicating that these cracks were not artificial. In contrast, only 29% of samples from patients with oral bisphosphonate medication without ONJ, no sample from patients with OM, none of the osteoradionecrosis group, and only 17% from patients with osteoporosis showed microcracks. Statistically significant differences could be found between the ONJ group and the group after irradiation and the group with OM, respectively. The evidence of microcracks could be a first step in the pathogenesis of bisphosphonate-related ONJ. The accumulation of these microcracks leads to a situation that could be named "non-symptomatic ONJ". Disruptions of the mucosal integrity may then allow bacterial invasion, leading to jawbone infection with exposed bone, fistulas, and pain. This state could be called "symptomatic ONJ". Furthermore, an assumed local immunosuppression as indicated by various studies could explain the severe courses of therapy-resistant ONJ as regularly observed.
Collapse
Affiliation(s)
- Sebastian Hoefert
- Department of Oral and Maxillofacial Surgery, Knappschaftskrankenhaus, Academic Teaching Hospital of the Ruhr-Universität Bochum, Dorstener Str 151, 45657 Recklinghausen, Germany.
| | | | | | | |
Collapse
|
24
|
Sunyecz J. Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clin Interv Aging 2009; 3:611-27. [PMID: 19281054 PMCID: PMC2682394 DOI: 10.2147/cia.s2496] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Postmenopausal osteoporosis is common and underrecognized among elderly women. Osteoporotic fractures cause disability and disfigurement and threaten patients' mobility, independence, and survival. Care for incident fractures in this age group must go beyond orthopedic repair, to assessment and treatment of the underlying bone fragility. Fracture risk can be reduced by vitamin D and calcium supplementation along with antiresorptive drug treatment. First-line osteoporosis pharmacotherapy employs nitrogen-containing bisphosphonates. The inconvenience of daily oral treatment has motivated development of weekly, monthly, and intermittent oral regimens, as well as quarterly and yearly intravenous (i.v.) regimens. Ibandronate is the first bisphosphonate to have shown direct anti-fracture efficacy with a non-daily regimen; it was approved for once-monthly oral dosing in 2005 and for quarterly i.v. dosing in 2006. Intermittent oral risedronate and yearly i.v. zoledronic acid were approved in 2007. Newly available regimens with extended dosing intervals reduce the inconvenience of bisphosphonate therapy and provide patients with a range of options from which to select a maximally sustainable course of treatment. This review discusses the development, efficacy, safety, and tolerability of extended-interval bisphosphonate regimens and examines their potential to improve patient acceptance and long-term success of osteoporosis treatment.
Collapse
Affiliation(s)
- John Sunyecz
- MenopauseRx, Inc., Laurel Highlands Ob/Gyn, P.C., 1142 National Pike Road, Hopwood, PA 15445, USA.
| |
Collapse
|
25
|
Osanai T, Tsuchiya T, Sugawara M. Rapid pain relief and marked sclerotic change of multiple bone metastases from a synovial sarcoma after treatment with intravenous pamidronate and chemotherapy. J Orthop Sci 2009; 14:224-7. [PMID: 19337817 DOI: 10.1007/s00776-008-1300-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2008] [Accepted: 08/25/2008] [Indexed: 10/20/2022]
Affiliation(s)
- Toshihisa Osanai
- Department of Orthopaedic Surgery, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan
| | | | | |
Collapse
|
26
|
Xiong Y, Yang HJ, Feng J, Shi ZL, Wu LD. Effects of Alendronate on the Proliferation and Osteogenic Differentiation of MG-63 Cells. J Int Med Res 2009; 37:407-16. [PMID: 19383235 DOI: 10.1177/147323000903700216] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Previous studies of the direct actions of bisphosphonates on bone have mainly been limited to their effects on bone-resorbing osteoclasts and little is known about the direct effects of bisphosphonates on osteoblasts. Here we report the direct effects of alendronate on the proliferation and osteogenic differentiation of the MG-63 osteoblast-like cell line. Cell proliferation was determined with the MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) assay, osteogenic differentiation was evaluated with an alkaline phosphatase bioassay and by analysis of gene expression by reverse transcription-polymerase chain reaction, and the extent of calcium deposition was measured using Alizarin Red S staining. Alendronate significantly increased cell numbers over control values, with the greatest effect at 10−8 M. Alkaline phosphatase activity and gene expression of bone morphogenetic protein 2, type I collagen and osteocalcin were increased after alendronate treatment. Alendronate also stimulated calcium deposition. We conclude that alendronate, apart from inhibiting osteoclastic bone resorption, is also a promoter of osteoblast proliferation and maturation.
Collapse
Affiliation(s)
- Y Xiong
- Department of Orthopaedics, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China
| | - HJ Yang
- Department of Orthopaedics, Traditional Chinese Medical Hospital, Hangzhou, China
| | - J Feng
- Bone and Joint Research Institute, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China
| | - ZL Shi
- Bone and Joint Research Institute, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China
| | - LD Wu
- Department of Orthopaedics, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China
| |
Collapse
|
27
|
Salvolini E, Orciani M, Vignini A, Di Primio R, Mazzanti L. The effects of disodium pamidronate on human polymorphonuclear leukocytes and platelets: an in vitro study. Cell Mol Biol Lett 2009; 14:457-65. [PMID: 19238333 PMCID: PMC6275572 DOI: 10.2478/s11658-009-0012-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2008] [Accepted: 02/16/2009] [Indexed: 11/21/2022] Open
Abstract
Recent reports have indicated that, as well as having antiresorptive effects, bisphosphonates could have an application as anti-inflammatory drugs. Our aim was to investigate whether this anti-inflammatory action could be mediated by the nitric oxide (NO) released by the leukocytes migrating to the site of inflammation. In particular, we investigated in vitro the intracellular calcium concentration ([Ca2+](i)), the level of NO released by PMN and platelets, and the PMN myeloperoxidase activity after incubation with disodium pamidronate, since there was a postulated modulatory effect of this aminosubstituted bisphosphonate on leukocytes both in vitro and in vivo. Our data shows that the pamidronate treatment provoked a significant increase in the [Ca2+](i) parallel to the enhancement in NO release, suggesting a possible activation of constitutive nitric oxide synthase, while the myeloperoxidase activity was significantly reduced. In conclusion, we hypothesized that treatment with pamidronate could stimulate NO-production by cells present near the bone compartment, thus constituting a protective mechanism against bone resorption occurring during inflammation. In addition, PMN- and platelet-derived NO could act as a negative feed-back signal to restrict the inflammatory processes.
Collapse
Affiliation(s)
- Eleonora Salvolini
- Department of Molecular Pathology and Innovative Therapies - Histology, Polytechnic University of Marche, Via Tronto 10/A, 60020, Ancona, Italy.
| | | | | | | | | |
Collapse
|
28
|
Biological Activity of Aminophosphonic Acids and Their Short Peptides. TOPICS IN HETEROCYCLIC CHEMISTRY 2009. [DOI: 10.1007/7081_2008_14] [Citation(s) in RCA: 85] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
29
|
Toussaint ND, Elder GJ, Kerr PG. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol 2008; 4:221-33. [PMID: 18987295 DOI: 10.2215/cjn.02550508] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Cardiovascular disease is highly prevalent in chronic kidney disease (CKD) and is often associated with increased vascular stiffness and calcification. Recent studies have suggested a complex interaction between vascular calcification and abnormalities of bone and mineral metabolism, with an inverse relationship between arterial calcification and bone mineral density (BMD). Although osteoporosis is recognized and treated in CKD 1 to 3, the interpretation of BMD levels in the osteoporotic range is controversial in CKD 4, 5, and 5D when renal osteodystrophy is generally present. In addition, there is a paucity of data for patients with CKD mineral and bone disorder (MBD), because studies using bisphosphonates in postmenopausal and glucocorticoid-induced osteoporosis have generally excluded patients with significant CKD. For these patients, treatment of low BMD using standard therapies for osteoporosis is not without potential for harm due to the possibility of worsening low bone turnover, osteomalacia, mixed uraemic osteodystrophy, and of exacerbated hyperparathyroidism; and bisphosphonates should only be used selectively and with caution. Some experimental and clinical studies have also suggested that bisphosphonates may reduce progression of extra-osseous calcification and inhibit the development of atherosclerosis. The authors review the potential benefits and risks associated with bisphosphonate use for bone protection in CKD, and assess their effect on vascular calcification and atherosclerosis.
Collapse
Affiliation(s)
- Nigel D Toussaint
- Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia.
| | | | | |
Collapse
|
30
|
Krauth MT, Fügl A, Gruber R. Bisphosphonat-assoziierte Osteonekrosen des Kieferknochens. Wien Klin Wochenschr 2008; 120:467-76. [DOI: 10.1007/s00508-008-1002-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2007] [Accepted: 06/17/2008] [Indexed: 01/23/2023]
|
31
|
Evans KD, Sheppard LE, Grossman DI, Rao SH, Martin RB, Oberbauer AM. Long Term Cyclic Pamidronate Reduces Bone Growth by Inhibiting Osteoclast Mediated Cartilage-to-Bone Turnover in the Mouse. Open Orthop J 2008; 2:121-5. [PMID: 19572021 PMCID: PMC2703200 DOI: 10.2174/1874325000802010121] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2008] [Revised: 06/17/2008] [Accepted: 06/24/2008] [Indexed: 11/22/2022] Open
Abstract
Bisphosphonates, used to treat diseases exhibiting increased osteoclast activity, reduce longitudinal bone growth through an as yet undefined mechanism. Pamidronate, an aminobisphosphonate, was given weekly to mice at 0, 1.25, or 2.50 mg/kg/wk beginning at 4 weeks of age. At 12 weeks of age, humeral length, growth plate area, regional chondrocyte cell numbers, chondrocyte apoptosis, TRAP stained osteoclast number, and osteoclast function assessed by cathepsin K immunohistochemistry were quantified. Humeral length was decreased in pamidronate treated mice compared to vehicle control mice, and correlated with greater growth plate areas reflecting greater proliferative and hypertrophic chondrocyte cell numbers with fewer hypertrophic cells undergoing apoptosis. Pamidronate treatment increased TRAP stained osteoclast numbers yet decreased cathepsin K indicating that pamidronate repressed osteoclast maturation and function. The data suggest that long term cyclic pamidronate treatment impairs bone growth by inhibition of osteoclast maturation thereby reducing cartilage-to-bone turnover within the growth plate.
Collapse
Affiliation(s)
- K D Evans
- Department of Animal Science, University of California, Davis, One Shields Avenue, Davis, CA 95616, USA
| | | | | | | | | | | |
Collapse
|
32
|
The Effects of Systemic Alendronate With or Without Intraalveolar Collagen Sponges on Postextractive Bone Resorption. J Craniofac Surg 2008; 19:1061-6. [DOI: 10.1097/scs.0b013e3180a0331a] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
33
|
Fu L, Tang T, Miao Y, Zhang S, Qu Z, Dai K. Stimulation of osteogenic differentiation and inhibition of adipogenic differentiation in bone marrow stromal cells by alendronate via ERK and JNK activation. Bone 2008; 43:40-47. [PMID: 18486585 DOI: 10.1016/j.bone.2008.03.008] [Citation(s) in RCA: 115] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2007] [Revised: 02/26/2008] [Accepted: 03/13/2008] [Indexed: 02/07/2023]
Abstract
To elucidate the mechanism of the effect of bisphosphonates on bone metabolism, we investigated the effect of alendronate, a widely used bisphosphonate, on osteogenic and adipogenic differentiation in bone marrow stromal cells (BMSCs) derived from ovariectomized SD rats. Alendronate treatment not only increased the mRNA level of bone morphogenetic protein-2, runt-related transcription factor 2, osteopontin, bone sialoprotein, and alkaline phosphatase activity after osteogenic induction, but also decreased the mRNA level of peroxisome proliferator activated receptor gamma 2 and total droplet number indicated by Oil Red O staining after adipogenic induction. The effect of alendronate treatment was dose-dependent, and the difference of the osteogenic or the adipogenic potential between the treated group and the non-treated group was statistically significant (p<0.001). The MAPK-specific inhibitors, PD98059 and SP600125, but not the p38-specific inhibitor, blocked the alendronate-induced regulation of BMSC differentiation. Analysis of BMSCs induced in the presence of alendronate revealed an immediate increase in ERK and JNK phosphorylation. Taken together, these data suggest that alendronate acts on BMSCs to stimulate osteogenic differentiation and inhibit adipogenic differentiation in a dose-dependent manner; this effect is mediated via activating ERK and JNK.
Collapse
Affiliation(s)
- Lingjie Fu
- Department of Orthopaedic Surgery, Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China; Orthopaedic Cellular and Molecular Biology Laboratory, Institute of Health Sciences, Chinese Academy of Sciences, and Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
| | - Tingting Tang
- Department of Orthopaedic Surgery, Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
| | - Yanying Miao
- Orthopaedic Cellular and Molecular Biology Laboratory, Institute of Health Sciences, Chinese Academy of Sciences, and Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
| | - Shuhong Zhang
- Department of Orthopaedic Surgery, Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
| | - Zhihu Qu
- Orthopaedic Cellular and Molecular Biology Laboratory, Institute of Health Sciences, Chinese Academy of Sciences, and Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
| | - Kerong Dai
- Department of Orthopaedic Surgery, Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, PR China; Orthopaedic Cellular and Molecular Biology Laboratory, Institute of Health Sciences, Chinese Academy of Sciences, and Shanghai Jiaotong University School of Medicine, Shanghai, PR China.
| |
Collapse
|
34
|
Jokihaara J, Pörsti IH, Kööbi P, Jolma PM, Mustonen JT, Saha HHT, Sievänen H, Kannus P, Iwaniec UT, Turner RT, Järvinen TLN. Treatment of experimental renal osteodystrophy with pamidronate. Kidney Int 2008; 74:319-27. [PMID: 18463610 DOI: 10.1038/ki.2008.180] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
We evaluated the effects of the bisphosphonate pamidronate on bone histomorphometry, structure and strength in male rats with uninephrectomy or with chronic renal disease induced by 5/6 nephrectomy. In rats with chronic renal disease the plasma urea, phosphate and parathyroid hormone levels were significantly increased compared to rats with a uninephroctomy and none of these parameters was affected by pamidronate treatment. In the femoral midshaft, chronic renal disease reduced cortical bone mineral density and content. No difference was observed in the breaking load of the femoral midshaft. In the distal femur, a high-turnover renal osteodystrophy was found but pamidronate suppressed this bone turnover and increased bone mineral content. Treatment had no effect on chronic disease-induced augmentation of osteoid volume or fibroblast surface. These studies show that in this model of stage 3 renal disease, pamidronate increased mineral content in the femoral midshaft and distal metaphysis primarily by adding bone to endocortical and trabecular surfaces but did not reduce osteitis fibrosa.
Collapse
Affiliation(s)
- Jarkko Jokihaara
- Department of Orthopaedics, University of British Columbia, Vancouver, British Columbia, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Emkey RD. Quarterly intravenous ibandronate for postmenopausal osteoporosis. WOMEN'S HEALTH (LONDON, ENGLAND) 2008; 4:219-228. [PMID: 19072470 DOI: 10.2217/17455057.4.3.219] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Osteoporosis is under-recognized and undertreated among postmenopausal women. Nitrogen-containing bisphosphonates are its first-line pharmacotherapy. Oral bisphosphonate treatment requires stringent dosing guidelines to minimize gastrointestinal irritation and enhance absorption. This paper reviews the efficacy, safety and tolerability of quarterly intravenous ibandronate 3 mg injection, approved in 2006 in the USA and Europe. Quarterly intravenous ibandronate injection has shown superior efficacy to daily oral ibandronate for bone mineral density increase and fracture prevention. No drug-related serious atrial fibrillation events have been reported with intravenous ibandronate. The regimen has a favorable renal safety profile. Quarterly intravenous ibandronate is administered as a simple 15-30-s intravenous injection in a physician's office and provides a beneficial option for patients who are unable to tolerate oral administration.
Collapse
Affiliation(s)
- Ronald D Emkey
- Emkey Osteoporosis & Arthritis Clinic, 1235 Penn Avenue, Suite 200, Wyomissing, PA 19610, USA.
| |
Collapse
|
36
|
Vovk AI, Chuííko AL, Kononets LA, Tanchuk VI, Murav'eva IV, Lozinskií MO, Kukhar' VP. [Inhibition of alkaline phosphatase by thioureido derivatives of methylenebisphosphonic acid]. RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY 2008; 34:67-74. [PMID: 18365740 DOI: 10.1134/s1068162008010081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
A series of thioureido derivatives of methylenebisphosphonic acid were synthesized by the reaction of aminomethylenebisphosphonic acid with the corresponding isothiocyanates, and their effect on the activity of alkaline phosphatases from bovine small intestine mucosa (BSIM) and human placenta was studied. It was found that (3-phenylthioureido)methylenebisphosphonate is approximately one order of magnitude more effective in inhibiting the activity of alkaline phosphatase from BSIM than the alkyl derivatives of thioureidomethylenebisphosphonic acid with methyl, ethyl, tert-butyl, or cyclohexyl substituents. The introduction of substituents into the benzene ring of (3-phenylthioureido)methylenebisphosphonate decreased the effect of the inhibitor on the activity of the enzyme. The affinity of (3-phenylureido)methylenebisphosphonate to the alkaline phosphatase of BSIM was also weaker as compared with the corresponding thioureidomethylenebisphosphonate. The insertion of thioureidobisphosphonates into the active site of alkaline phosphatase of human placenta by the method of molecular docking indicated that the methylenebisphosphonate residue and the substituted amino groups of the inhibitor are involved in the mechanisms of complex formation with the enzyme. It is supposed that the improvement of the inhibitory activity of (3-phenylthioureido)methylenebisphosphonate toward alkaline phosphatase of BSIM is due to the additional fixation of the phenyl substituent in the active site of the enzyme.
Collapse
|
37
|
Sun S. Bone disease drug discovery: examining the interactions between osteoblast and osteoclast. Expert Opin Ther Targets 2008; 12:239-51. [DOI: 10.1517/14728222.12.2.239] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
38
|
Bisphosphonate treatment and radiotherapy in metastatic breast cancer. Med Oncol 2008; 25:350-5. [PMID: 18202925 DOI: 10.1007/s12032-008-9044-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2007] [Accepted: 12/17/2007] [Indexed: 10/22/2022]
Abstract
Patients with advanced breast cancer frequently develop metastasis to bone. Bone metastasis results in intractable pain and high risk of pathologic fractures due to osteolysis. The treatment of breast cancer patients with bone metastases requires a multidisciplinary approach. Radiotherapy is an established treatment for metastatic bone pain. It may be delivered either as a localized low dose treatment for localized bone pain or systemically for more widespread symptoms. Bisphosphonates have been shown to reduce morbidity and bone pain from bone metastases when given to patients with metastatic bone disease. In vivo studies indicate that early bisphosphonates administration in combination with radiotherapy improves remineralization and restabilization of osteolytic bone metastases in animal tumor models. This review focused on a brief discussion about biology of bone metastases, the effects of radiotherapy and bisphosphonate therapy, and possible mechanisms of combination therapy in metastatic breast cancer patients.
Collapse
|
39
|
Saitoh A, Narita M, Watanabe N, Tochiki N, Satoh N, Takizawa J, Furukawa T, Toba K, Aizawa Y, Shinada S, Takahashi M. Anti-tumor cytotoxicity of γδ T cells expanded from peripheral blood cells of patients with myeloma and lymphoma. Med Oncol 2007; 25:137-47. [DOI: 10.1007/s12032-007-9004-4] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2007] [Accepted: 07/16/2007] [Indexed: 11/29/2022]
|
40
|
Issack PS, Lauerman MH, Helfet DL, Doty SB, Lane JM. Alendronate inhibits PTH (1-34)-induced bone morphogenetic protein expression in MC3T3-E1 preosteoblastic cells. HSS J 2007; 3:169-72. [PMID: 18751789 PMCID: PMC2504255 DOI: 10.1007/s11420-007-9042-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/19/2006] [Accepted: 03/06/2007] [Indexed: 02/07/2023]
Abstract
The bisphosphonate class of antiresorptive drugs and active forms of parathyroid hormone (PTH (1-34)) have been used clinically to enhance bone mass and density in patients with osteoporosis. Abundant evidence suggests that the mechanism by which PTH (1-34) increases bone density is stimulation of osteoblast differentiation. Although bisphosphonates have been classically thought to increase bone density by inhibiting osteoclasts, there is increasing evidence to suggest that bisphosphonates have direct stimulatory effects on osteoblast differentiation. Interestingly, in patients with osteoporosis, combination therapy with bisphosphonates and PTH (1-34) is not synergistic in increasing bone density; bisphosphonates appear to blunt the effect of PTH (1-34). To begin to understand the mechanism governing the effects of these agents on osteoblasts and a possible explanation for their apparent antagonism, we examined the expression of several bone morphogenetic proteins (BMPs) in MC3T3-E1 preosteoblastic cells either untreated, or treated with alendronate, parathyroid hormone, or a combination of the two agents. We find by reverse transcriptase-polymerase chain reaction (RT-PCR) that while alendronate fails to induce the expression of any of the BMPs tested, several BMPs are induced by PTH (1-34). The induction of the PTH (1-34)-inducible BMPs is blocked with simultaneous alendronate treatment. These data suggest that alendronate interferes with PTH (1-34)-induced BMP gene transcription and provides a possible basis for the antagonism observed between the two agents in increasing bone density.
Collapse
Affiliation(s)
- Paul S. Issack
- Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021 USA
| | | | - David L. Helfet
- Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021 USA
| | - Stephen B. Doty
- Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021 USA
| | - Joseph M. Lane
- Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021 USA
| |
Collapse
|
41
|
Schindeler A, Little DG. Bisphosphonate action: Revelations and deceptions from in vitro studies. J Pharm Sci 2007; 96:1872-8. [PMID: 17518363 DOI: 10.1002/jps.20904] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Bisphosphonates (BPs) are a class of drugs used in the treatment of osteoporosis and diseases of high bone turnover, as well as for control of skeletal related events secondary to malignant disease. The key to BP specificity is their capacity to bind rapidly and with high affinity to bone surfaces. The cellular targets of BPs at the bone surface have been a source of controversy. In addition to osteoclasts, it has been frequently proposed that BPs may affect a variety of cell types including osteoclast precursors, osteoblasts and bone-lining cells, immunogenic cells, and tumour cells. However, there is an emerging body of literature from in vitro studies indicating that BPs are only released and taken up from bone surfaces by resorbing osteoclasts. In this scenario, the only significant exposure of non-resorbing cells to BP would occur during the initial period after dosing, prior to drug clearance from the soft tissues. Auspiciously, several groups have reported on revised culture systems that better reflect the pharmacology of BP dosing.
Collapse
Affiliation(s)
- Aaron Schindeler
- Department of Orthopaedic Research & Biotechnology, The Children's Hospital at Westmead, Sydney, Australia
| | | |
Collapse
|
42
|
Deng X, Yu Z, Funayama H, Yamaguchi K, Sasano T, Sugawara S, Endo Y. Histidine decarboxylase-stimulating and inflammatory effects of alendronate in mice: Involvement of mevalonate pathway, TNFα, macrophages, and T-cells. Int Immunopharmacol 2007; 7:152-61. [PMID: 17178381 DOI: 10.1016/j.intimp.2006.09.009] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2006] [Revised: 09/07/2006] [Accepted: 09/07/2006] [Indexed: 12/31/2022]
Abstract
Nitrogen-containing bisphosphonates (NBPs) are powerful anti-bone-resorptive drugs, but they frequently induce various inflammatory side effects. Recent clinical applications have disclosed an unexpected new side effect, jaw-bone necrosis and exposure. In vitro studies suggest that the inflammatory effects of NBPs are due to Vgamma2Vdelta2 T-cells, stimulated directly and/or indirectly [the latter via isopentenylpyrophosphate (IPP) in the mevalonate pathway]. Rats and mice, however, lack Vgamma2Vdelta2 T-cells, yet NBPs still induce necrotic and inflammatory reactions. In mice, NBPs induce IL-1-dependent inflammatory reactions, such as inductions of histidine decarboxylase (HDC, the histamine-forming enzyme) in the liver, lung, spleen, and bone marrow, an increase in granulocytic cells in the peritoneal cavity, pleural exudation, and splenomegaly. Here, we examined the involvement of IPP, TNF, macrophages, and T-cells in the inflammatory actions of alendronate (a typical NBP) in mice. Various statins (mevalonate-synthesis inhibitors) suppressed the alendronate-induced HDC inductions, while mevalonate itself augmented such inductions. IPP injection also induced HDC. Like IL-1-deficient mice, TNF-deficient mice were resistant to alendronate-stimulated HDC induction. Alendronate-stimulated HDC inductions were significantly weaker in macrophage-depleted mice and in nude mice than in control mice. Similar, though generally less clear-cut, results were obtained when other alendronate-induced inflammatory reactions were examined. These results suggest that (i) inhibition of the mevalonate pathway causes and/or modifies at least some inflammatory actions of alendronate in mice, (ii) in addition to IL-1, TNF is also involved in the inflammatory actions of alendronate, and (iii) alendronate may act on a variety of cells, including macrophages and T-cells.
Collapse
Affiliation(s)
- Xue Deng
- Department of Molecular Regulation, Graduate School of Dentistry, Tohoku University, 4-1 Seiryo-Machi, Sendai, Japan
| | | | | | | | | | | | | |
Collapse
|
43
|
Graziani F, Cei S, La Ferla F, Cerri E, Itro A, Gabriele M. Association between osteonecrosis of the jaws and chronic high-dosage intravenous bisphosphonates therapy. J Craniofac Surg 2007; 17:876-9. [PMID: 17003614 DOI: 10.1097/01.scs.0000221517.80361.6f] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Bisphosphonates (BPs) are used to inhibit bone resorption. Recently, they have been used in cancer patients to prevent bone loss due to bone metastasis. Fourteen consecutive patients, undergoing BPs monthly IV infusion due to neoplastic bone diseases, were diagnosed with osteonecrosis of the jaws. None of the patients had been previously undergoing radiotherapy of the head and neck region. Eight patients showed maxillary involvement, and nine patients had had a recent tooth extraction in the osteonecrosis areas. Biopsies and surgical debridment were performed. Histologically, none of the patients showed signs of bone metastasis. As high-dosage long-term BP therapy appears to be associated with osteonecrosis of the jaws, dental practitioners should exercise caution in the treatment of such patients.
Collapse
Affiliation(s)
- Filippo Graziani
- Department of Neurosciences, Section of Oral Surgery, University of Pisa, Pisa, Italy.
| | | | | | | | | | | |
Collapse
|
44
|
Elad S, Yarom N, Hamed W, Ayalon S, Yahalom R, Regev E. Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: a comparative study focused on multiple myeloma. ACTA ACUST UNITED AC 2006; 28:393-8. [PMID: 17105493 DOI: 10.1111/j.1365-2257.2006.00841.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
It was reported that multiple myeloma (MM)-patients suffer from a higher incidence of osteomyelitis and necrosis of the jaws than patients treated with bisphosphonates for other reasons. The aim of this study is to report about 57 cases of bisphosphonate-related osteomyelitis and necrosis of the jaws (BON) and to investigate the differences between BON in MM and non-MM patients. Clinical and laboratory data of 57 cases were assessed. The features of BON and clinical-outcome were compared between the two groups. Treatment approach was assessed as a contributing-factor to treatment-outcome. Clinical presentation included exposed bone, pain, swelling and suppuration with little variation between the two groups. Past dento-alveolar surgery was common in both study-groups. Treatment outcome was poor (33% and 25% responded to treatment in MM group and non-MM group, respectively). Treatment modality did not affect the treatment outcome. The clinical presentation described in this case series should alert the physician to the possibility of BON. Although the literature shows a higher incidence of BON in MM patients compared to non-MM patients, our study suggests that the severity of the clinical presentation and the response to treatment are not worse in MM patients compared with non-MM patients. The predisposition of MM patients to BON should be further investigated.
Collapse
Affiliation(s)
- S Elad
- Department of Oral Medicine, The Hebrew University-Hadassah School of Dental Medicine, Jerusalem 91120, Israel.
| | | | | | | | | | | |
Collapse
|
45
|
Ribatti D, Nico B, Mangieri D, Maruotti N, Longo V, Vacca A, Cantatore FP. Neridronate inhibits angiogenesis in vitro and in vivo. Clin Rheumatol 2006; 26:1094-8. [PMID: 17106617 DOI: 10.1007/s10067-006-0455-3] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2006] [Revised: 09/19/2006] [Accepted: 09/19/2006] [Indexed: 10/23/2022]
Abstract
The effects of the amino-bisphosphonate neridronate on endothelial cell functions involved in angiogenesis, namely, proliferation and morphogenesis on Matrigel were tested in vitro, whereas its effects on angiogenesis were studied in vivo, by using the chick embryo chorioallantoic membrane (CAM) assay. In vitro, neridronate inhibited endothelial cell proliferation in a dose-dependent fashion, peaking at 30 microM. At the same concentration, neridronate inhibited fibroblast growth factor-2 (FGF-2)-induced capillary-like tube formation in the morphogenesis assay on Matrigel. In vivo, when tested in the CAM assay, neridronate again displayed the capability to inhibit FGF-2-induced angiogenesis. Overall, these results suggest that anti-angiogenesis by neridronate could be used to treat a wide spectrum of angiogenesis-dependent diseases, including certain chronic inflammatory diseases and cancer.
Collapse
Affiliation(s)
- D Ribatti
- Department of Human Anatomy and Histology, University of Bari Medical School, Policlinico, Piazza Giulio Cesare, 11, 70124 Bari, Italy.
| | | | | | | | | | | | | |
Collapse
|
46
|
Dickson PV, Hamner JB, Cauthen LA, Ng CYC, McCarville MB, Davidoff AM. Efficacy of zoledronate against neuroblastoma. Surgery 2006; 140:227-35. [PMID: 16904974 DOI: 10.1016/j.surg.2006.02.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2005] [Revised: 01/26/2006] [Accepted: 02/03/2006] [Indexed: 11/26/2022]
Abstract
BACKGROUND We investigated the antitumor and antiosteoclastic effects of zoledronate against human neuroblastoma in vitro and in a murine model of bone metastasis. METHODS Antitumor activity of zoledronate against neuroblastoma cell lines was assessed by evaluating proliferation, apoptosis, and cell-cycle progression. A murine model of bone invasion was used to assess antiosteoclastic and antitumor activity in vivo. Mice were followed by radiographic and bioluminescence imaging. RESULTS Treatment of human neuroblastoma cells resulted in a decrease in cell count, increase in apoptosis, and arrest of cell-cycle progression. In the model of bone invasion, mice were treated weekly with zoledronate or vehicle control 10 days after tumor cell inoculation. Five weeks later, radiographs revealed a large degree of osteolytic disease in control mice. Impressively, mice treated with zoledronate demonstrated minimal radiographic changes at this time. Bioluminescence imaging of these mice revealed a significant restriction of tumor growth during the course of therapy. CONCLUSIONS Zoledronate exhibits significant antitumor activity against human neuroblastoma cells in vitro, prevents development of osteolytic lesions, and restricts tumor growth in a murine model of bone metastasis. These results suggest that clinical investigation of zoledronate or similar bisphosphonates as adjuvant therapy in neuroblastoma patients is warranted.
Collapse
Affiliation(s)
- Paxton V Dickson
- Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | | | | | | | | | | |
Collapse
|
47
|
Srikulmontree T, Massey HD, Roberts WN. Treatment of skeletal Erdheim–Chester disease with zoledronic acid: case report and proposed mechanisms of action. Rheumatol Int 2006; 27:303-7. [PMID: 16932956 DOI: 10.1007/s00296-006-0190-8] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2006] [Accepted: 07/23/2006] [Indexed: 11/25/2022]
Abstract
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by tissue infiltration of lipid-laden macrophages, multinucleated giant cells, and inflammatory infiltrate of lymphocytes and histiocytes. The disease typically involves long bone, but may also affect the central nervous system, the orbit, retroperitoneal organs, and the lungs. Patients with visceral involvement tend to have poorer outcome. There is no proven effective treatment for ECD to date. However, recent data suggested the potential use of bisphosphonates for the treatment of this rare disease. Here we report a case of biopsy-proven skeletal ECD, who received treatment with zoledronic acid, an aminobisphosphonate, with remarkable clinical improvement. We also discuss possible mechanisms of action of bisphosphonates in this disorder, especially their roles in inhibition of inflammatory cytokines and macrophage infiltration.
Collapse
Affiliation(s)
- Thitinan Srikulmontree
- Rheumatology Section, Hunter Holmes McGuire Medical Center, 1201 Broad Rock Blvd, 111M, Richmond, VA 23249, USA.
| | | | | |
Collapse
|
48
|
Watanabe N, Narita M, Yokoyama A, Sekiguchi A, Saito A, Tochiki N, Furukawa T, Toba K, Aizawa Y, Takahashi M. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate. Cytotherapy 2006; 8:118-29. [PMID: 16698685 DOI: 10.1080/14653240600620200] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
BACKGROUND In order to establish efficient gammadelta T-cell based tumor immunotherapy, we explored a method to enhance the cytotoxicity of gammadelta T cells against leukemia cells by stimulating gammadelta T cells with type I IFN. METHODS Gammadelta T cells were expanded from normal PBMC by culturing with zoledronate and a low concentration of IL-2 for 2 weeks. For the activation of gammadelta T cells, gammadelta T cells were cultured with type I IFN (HLBI, IFN-alpha2b and IFN-beta) for 1-3 days. The cytotoxicity of HLBI-activated gammadelta T cells against leukemia cell lines and fresh leukemia cells was evaluated by 51Cr-release assay. RESULTS Gammadelta T cells, which were expanded and purified with magnetic beads using an anti-gammadelta TCR MAb, were demonstrated to be cytotoxic against leukemia cell lines of both lymphoid and myeloid origin and fresh myeloid leukemia cells. By culturing expanded gammadelta T cells with type I IFN, the expression of the activation marker CD69 was increased and the cytometric bead array showed an elevated production of IFN-gamma by gammadelta T cells. In addition, the cytotoxicity of gammadelta T cells against leukemia cells was definitely enhanced by culturing gammadelta T cells with HLBI. DISCUSSION The present study has demonstrated that type I IFN could enhance the anti-leukemic cytotoxicity of expanded gammadelta T cells, which implies that in vitro bisphosphonate (such as zoledronate)-expanded and type I IFN-activated gammadelta T cells could be applied to immunotherapy for hematologic malignancies such as leukemia and lymphoma.
Collapse
MESH Headings
- Antigens, CD/immunology
- Antigens, CD/metabolism
- Antigens, Differentiation, T-Lymphocyte/immunology
- Antigens, Differentiation, T-Lymphocyte/metabolism
- Cell Proliferation/drug effects
- Cells, Cultured
- Cytotoxicity, Immunologic/drug effects
- Diphosphonates/pharmacology
- Dose-Response Relationship, Immunologic
- Humans
- Imidazoles/pharmacology
- Immunotherapy, Adoptive
- Interferon Type I/pharmacology
- Interferon Type I/physiology
- Interferon-gamma/blood
- Interleukin-2/pharmacology
- Lectins, C-Type
- Leukocytes, Mononuclear/drug effects
- Leukocytes, Mononuclear/immunology
- Leukocytes, Mononuclear/metabolism
- Lymphocyte Activation/drug effects
- Lymphocyte Activation/immunology
- Receptors, Antigen, T-Cell, gamma-delta/immunology
- Receptors, Antigen, T-Cell, gamma-delta/metabolism
- T-Lymphocytes/drug effects
- T-Lymphocytes/immunology
- T-Lymphocytes/metabolism
- Tumor Cells, Cultured
- Zoledronic Acid
Collapse
Affiliation(s)
- N Watanabe
- Division of Hematology and Oncology, Graduate School of Health Sciences, Niigata, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Leite AF, Figueiredo PT, Melo NS, Acevedo AC, Cavalcanti MGP, Paula LM, Paula AP, Guerra ENS. Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review. ACTA ACUST UNITED AC 2006; 102:14-21. [PMID: 16831667 DOI: 10.1016/j.tripleo.2005.10.045] [Citation(s) in RCA: 48] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2005] [Revised: 09/22/2005] [Accepted: 10/17/2005] [Indexed: 11/26/2022]
Abstract
This paper reviews the main aspects involved in the bisphosphonate-associated osteonecrosis of the jaws and report its occurrence in a 82-year-old man, who had received long-term treatment with zoledronate to manage bone metastases due to prostate cancer. The clinical aspects and the treatment are presented. Computerized tomography contributed to a more specific diagnosis, demonstrating the osteonecrosis in the maxilla, sinus involvement, and sclerotic areas in the entire body of the mandible and c-spine. Clinical trials and studies in animals are necessary to elucidate the pathogenesis of bisphosphonate-associated osteonecrosis of the jaws, and to determine whether the bisphosphonates produce sclerotic changes in the skeleton similar to those found in osteopetrosis. Nevertheless, patients taking bisphosphonates should receive prophylactic attention to maintain their oral health. Preventive measures must be taken before, during, and after treatment with bisphosphonates.
Collapse
Affiliation(s)
- André Ferreira Leite
- Oral Radiology, Department of Dentistry, University of Brasília, Brasília, Brazil.
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 2006; 39:35-41. [PMID: 16434248 DOI: 10.1016/j.bone.2005.12.004] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/17/2005] [Revised: 10/22/2005] [Accepted: 12/04/2005] [Indexed: 12/21/2022]
Abstract
PURPOSE We evaluated the pain response and daily discomfort in patients with painful bone metastases treated by merging 89Sr-chloride and zoledronic acid. The results were compared with those of patients who received 89Sr-chloride or zoledronic acid separately. METHODS 25 patients (12 women; mean age 65+/-13 years) chronically treated with zoledronic acid underwent bone pain palliation with 150 MBq of 89Sr-chloride at least 6 months later that bisphoshonate therapy started (group A). 13 patients (6 women; mean age 70+/-12 years) received 89Sr-chloride alone (group B) and 11 patients (5 women; mean age 69+/-12 years) were chronically treated and continued to receive only zoledronic acid therapy (group C), both constituted the control groups. Patients kept a daily pain diary assessing both their discomfort and the pain of specific sites by using a visual analog scale (VAS), rating from 0 (no d iscomfort-no pain) to 10 (worst discomfort-pain). These diaries were reviewed weekly for 2 months and three different physicians rated the pain response on a scale of -2 (considerable deterioration) to +2 (considerable improvement). RESULTS Baseline characteristics were similar in the three groups. The reduction of total discomfort and of bone pain in the group A was significantly greater as compared to group B (P<0.01) and group C (P<0.01). During the monitored period, a significant improvement of clinical conditions was observed in the group A, varying the rate from -1 to 1 as compared to both groups B and C in which the rate changed from -1 to 0. CONCLUSION Our findings indicate that combined therapy of 89Sr-chloride and zoledronic acid in patients with painful bone metastases is more effective in treating pain and improving clinical conditions than 89Sr-chloride or zoledronic acid used separately.
Collapse
Affiliation(s)
- Giovanni Storto
- Institute of Biostructures and Bioimages, National Council of Research, Naples, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|